BioCentury | Dec 14, 2018
Clinical News

Netris' NTN1 inhibitor safe in Phase I for solid tumors

...24 patients. NP137 is a humanized IgG1 mAb against netrin 1 (NTN1). Early next year, Netris...
...treatments with NP137, with the goal of starting a European Phase Ib/II trial in 3Q19. Netris...
...useful in combinations to root out slowly proliferating cancer stem cells (see "Restoring Dependence" ). Netris Pharma S.A.S....
BioCentury | Aug 19, 2017
Product Development

Restoring dependence

...the receptor, impairment of signaling downstream from the receptor, or overexpression of the receptors’ ligands. Netris...
...of the combination is rather linked to the effect on slowly proliferating cells.” Patrick Mehlen, Netris...
...and preventing it from interacting with its dependence receptor. Source: Netris Companies and Institutions Mentioned Netris Pharma S.A.S....
BioCentury | Mar 29, 2017
Clinical News

NP137: Ph I started

...determine the recommended Phase II dose, which will be evaluated in the expansion part 2. Netris Pharma S.A.S....
...response and clinical benefit rate (CBR) Status: Phase I started Milestone: Phase I data (2017) Nora Weintraub NP137 Netris Pharma S.A.S. Netrin...
BioCentury | Sep 12, 2013
Distillery Therapeutics

Indication: Cancer

...the identified inhibitor. SciBX 6(35); doi:10.1038/scibx.2013.955 Published online Sept. 12, 2013 Patent application filed by Netris...
BioCentury | Mar 4, 2010
Distillery Therapeutics

Indication: Cancer

...of the NTF3-TrkC interaction. SciBX 3(9); doi:10.1038/scibx.2010.276 Published online March 4, 2010 Patented; licensed to Netris...
BioCentury | Apr 16, 2009
Distillery Therapeutics

This week in therapeutics

...the antiapoptotic mechanism triggered by NTN1 inhibition and identifying interactions between NTN1 and other receptors. Netris...
...and other cancers. SciBX 2(15); doi:10.1038/scibx.2009.616 Published online April 16, 2009 Patented; exclusively licensed to Netris...
BioCentury | Feb 19, 2009
Distillery Therapeutics

Indication: Cancer

...low levels of NTN1. Ongoing work is examining NTN1 expression in additional types of NSCLC. Netris...
...target NTN1-UNC5H interactions. SciBX 2(7); doi:10.1038/scibx.2009.269 Published online Feb. 19, 2009 Patented; exclusively out-licensed to Netris...
BioCentury | Apr 3, 2008
Distillery Therapeutics

This Week in Therapeutics

...inhibitory activity of netrin-1 on receptor-induced cell death. Next steps include developing biologics targeting netrin-1. Netris Pharma S.A.S....
...for anticancer compounds using netrin-1 activity patented by Centre National de la Recherche Scientifique (CNRS); Netris Pharma S.A.S....
Items per page:
1 - 8 of 8
BioCentury | Dec 14, 2018
Clinical News

Netris' NTN1 inhibitor safe in Phase I for solid tumors

...24 patients. NP137 is a humanized IgG1 mAb against netrin 1 (NTN1). Early next year, Netris...
...treatments with NP137, with the goal of starting a European Phase Ib/II trial in 3Q19. Netris...
...useful in combinations to root out slowly proliferating cancer stem cells (see "Restoring Dependence" ). Netris Pharma S.A.S....
BioCentury | Aug 19, 2017
Product Development

Restoring dependence

...the receptor, impairment of signaling downstream from the receptor, or overexpression of the receptors’ ligands. Netris...
...of the combination is rather linked to the effect on slowly proliferating cells.” Patrick Mehlen, Netris...
...and preventing it from interacting with its dependence receptor. Source: Netris Companies and Institutions Mentioned Netris Pharma S.A.S....
BioCentury | Mar 29, 2017
Clinical News

NP137: Ph I started

...determine the recommended Phase II dose, which will be evaluated in the expansion part 2. Netris Pharma S.A.S....
...response and clinical benefit rate (CBR) Status: Phase I started Milestone: Phase I data (2017) Nora Weintraub NP137 Netris Pharma S.A.S. Netrin...
BioCentury | Sep 12, 2013
Distillery Therapeutics

Indication: Cancer

...the identified inhibitor. SciBX 6(35); doi:10.1038/scibx.2013.955 Published online Sept. 12, 2013 Patent application filed by Netris...
BioCentury | Mar 4, 2010
Distillery Therapeutics

Indication: Cancer

...of the NTF3-TrkC interaction. SciBX 3(9); doi:10.1038/scibx.2010.276 Published online March 4, 2010 Patented; licensed to Netris...
BioCentury | Apr 16, 2009
Distillery Therapeutics

This week in therapeutics

...the antiapoptotic mechanism triggered by NTN1 inhibition and identifying interactions between NTN1 and other receptors. Netris...
...and other cancers. SciBX 2(15); doi:10.1038/scibx.2009.616 Published online April 16, 2009 Patented; exclusively licensed to Netris...
BioCentury | Feb 19, 2009
Distillery Therapeutics

Indication: Cancer

...low levels of NTN1. Ongoing work is examining NTN1 expression in additional types of NSCLC. Netris...
...target NTN1-UNC5H interactions. SciBX 2(7); doi:10.1038/scibx.2009.269 Published online Feb. 19, 2009 Patented; exclusively out-licensed to Netris...
BioCentury | Apr 3, 2008
Distillery Therapeutics

This Week in Therapeutics

...inhibitory activity of netrin-1 on receptor-induced cell death. Next steps include developing biologics targeting netrin-1. Netris Pharma S.A.S....
...for anticancer compounds using netrin-1 activity patented by Centre National de la Recherche Scientifique (CNRS); Netris Pharma S.A.S....
Items per page:
1 - 8 of 8